SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Rhea-AI Summary

SCYNEXIS (NASDAQ: SCYX) received a 180-calendar-day extension from Nasdaq to regain compliance with the minimum bid price rule, extending the cure period to June 15, 2026.

Nasdaq confirmed SCYNEXIS meets other continued listing criteria and the company said it may use a reverse stock split if needed. Management also confirmed plans to complete a Phase 1 IV study and seek proof-of-concept Phase 2 oral data for investigational antifungal SCY-247 in invasive candidiasis, while maintaining commitments to regain full Nasdaq compliance.

Positive

• Nasdaq extension granted until June 15, 2026
• Company meets other Nasdaq continued listing criteria
• Planned Phase 1 IV study completion for SCY-247

Negative

• Shares remain below the <$1.00 bid price requirement
• Possible reverse stock split could affect shareholder liquidity

Key Figures

Extension period 180 calendar days Additional Nasdaq compliance window for minimum bid price

Compliance deadline June 15, 2026 Date by which SCYX must regain $1.00 bid for 10 days

Bid price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) minimum bid threshold

Consecutive days 10 business days Duration closing bid must stay at or above $1.00

Phase 1 study Phase 1 Planned IV formulation trial for SCY-247

Phase 2 data Phase 2 Planned proof-of-concept oral SCY-247 in invasive candidiasis

Share price $0.627 Price before news, below Nasdaq $1.00 threshold

52-week range $0.565–$1.49 SCYX 52-week low and high before this announcement

Market Reality Check

$0.6270 Last Close

Volume Today's volume 235,170 is about 0.7x the 20-day average of 333,730, indicating subdued trading ahead of this compliance update. normal

Technical At $0.627, shares are trading below the 200-day MA of $0.82 and sit well under the $1.00 Nasdaq bid requirement, while hovering above the 52-week low of $0.565.

Peers on Argus 1 Up 1 Down

Sector peers show mixed moves, with examples like IXHL up 6.8% and TLPH down 0.9%. Momentum scanner names (e.g., FLGC up 18.6%, RMTI down 4.62%) also move in both directions, suggesting this Nasdaq compliance extension is more stock-specific than sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 19	NDA transfer update	Positive	+1.8%	Completion of BREXAFEMME NDA transfer to GSK with milestone potential.
Nov 17	Collaboration funding	Positive	-1.4%	Federal grant supporting novel fungerp development via CETR collaboration.
Nov 05	Earnings & update	Positive	+0.1%	Q3 2025 results, GSK payment, over two-year cash runway guidance.
Oct 15	MARIO resolution	Positive	-0.3%	GSK agreement to terminate MARIO with payments and extended runway.
Sep 30	Phase 1 results	Positive	-26.7%	Positive Phase 1 safety and PK data for second‑generation fungicide SCY-247.

Pattern Detected

Recent news has often been positive operationally, but price reactions skew mixed-to-negative, including a sharp selloff on favorable Phase 1 data.

Recent Company History

Over the past few months, SCYNEXIS announced multiple positive developments, including favorable Phase 1 results for SCY-247 on Sep 30, a cash-extending MARIO resolution on Oct 15, and Q3 2025 results with a planned IV Phase 1 and Phase 2 oral study. Additional updates on the BREXAFEMME NDA transfer and federal funding for next‑generation fungerps highlighted strategic progress. Today’s Nasdaq compliance extension fits into a broader backdrop of clinical and partnership advances alongside listing-standard pressures.

Market Pulse Summary

This announcement grants SCYNEXIS a further 180 days, until June 15, 2026, to regain compliance with Nasdaq’s $1.00 minimum bid price rule, with the possibility of using a reverse stock split if needed. It comes against a backdrop of recent clinical and partnership milestones and a share price of $0.627, below the $1.00 requirement but above the 52-week low. Key items to watch include execution of the planned Phase 1 IV and Phase 2 oral studies for SCY-247 and future listing-status updates.

Key Terms

minimum bid price requirement regulatory

"to regain compliance with the minimum bid price requirement, as outlined in Nasdaq"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

reverse stock split financial

"intention to cure the deficiency within the extension period, if necessary, through a reverse stock split."

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

intravenous (iv) medical

"complete a Phase 1 study of an intravenous (IV) formulation for our next-generation"

A method of delivering fluids, medicines or nutrients directly into a vein through a needle or tube so they enter the bloodstream immediately, like sending a package straight to the main highway instead of along side roads. Investors care because intravenous delivery affects how fast and reliably a treatment works, the complexity and cost of products and devices, hospital and clinic use, regulatory scrutiny and reimbursement — all of which influence commercial value.

phase 1 medical

"leverage our balance sheet to complete a Phase 1 study of an intravenous (IV)"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2 medical

"as well as generate proof-of-concept Phase 2 data in the oral formulation"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

proof-of-concept technical

"as well as generate proof-of-concept Phase 2 data in the oral formulation"

A proof-of-concept is a demonstration that shows a new idea or method can work as intended, serving as a small-scale test before full development. For investors, it signals that a concept has been successfully tested in principle, reducing uncertainty about whether it can be practically implemented. This helps determine if further investment or effort is justified to develop the idea further.

AI-generated analysis. Not financial advice.

JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2).

The Company now has until June 15, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq granted the extension after determining that SCYNEXIS continues to meet all other continued listing criteria for the Nasdaq Capital Market, including the market value of publicly held shares, and has provided written notice of its intention to cure the deficiency within the extension period, if necessary, through a reverse stock split.

“We are grateful for Nasdaq’s decision to grant this 180-day extension, which allows us to continue advancing our strategic objectives,” said David Angulo, M.D., President and Chief Executive Officer. “In the upcoming year we expect to leverage our balance sheet to complete a Phase 1 study of an intravenous (IV) formulation for our next-generation fungerp, SCY-247, as well as generate proof-of-concept Phase 2 data in the oral formulation of SCY-247 for invasive candidiasis infections. SCY-247 is an exciting investigational antifungal with the potential to benefit both hospitalized and community patients with challenging infections and is highly anticipated by the anti-infective scientific community. Lastly, SCYNEXIS remains committed to full compliance with all Nasdaq listing requirements and plans to take all necessary actions within the prescribed 180-day period to regain compliance.”

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) has approved BREXAFEMME^® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC. Additional antifungal assets from this novel class are currently in clinical, pre-clinical and discovery phases, including the compound SCY-247. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: regaining Nasdaq compliance, completing a Phase 1 study of an IV formulation for SCY-247, generating proof-of-concept Phase 2 data in the oral formulation of SCY-247 for invasive candidiasis infections, and the potential benefits of SCY-247. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: 917-734-7387
ikoffler@lifesciadvisors.com 

FAQ

What Nasdaq action did SCYNEXIS (SCYX) receive on December 22, 2025?

SCYNEXIS received a 180-calendar-day extension to regain the minimum $1.00 bid-price compliance.

What is the deadline for SCYNEXIS (SCYX) to regain Nasdaq compliance?

The company has until June 15, 2026 to meet the $1.00 minimum bid price for 10 consecutive business days.

Will SCYNEXIS (SCYX) face delisting immediately after the extension?

No; Nasdaq granted an extension and confirmed SCYNEXIS meets other listing criteria while the cure period runs.

Could SCYNEXIS (SCYX) use a reverse stock split to regain compliance?

Yes; the company stated it may implement a reverse stock split within the extension period if necessary.

What clinical plans did SCYNEXIS announce for SCY-247 in 2026?

SCYNEXIS plans to complete a Phase 1 IV study and pursue proof-of-concept Phase 2 oral data for SCY-247.